Dylan Van Haaften

GENMAB NEUTRAL | DKK2100 Genmab: Upgrading to neutral, positive 1Q data, trends, and execution, but is it enough?

º Reported positive Q1 22 earnings, beating consensus numbers, and guided up the 2022 revenue.
We are becoming increasingly more positive about epcoritamab due to four reasons…
We are upgrading the rating to Neutral (from Sell) and upgrading the TP to DKK 2,100 (from DKK 2000).
Genmab A/S

Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s product pipeline includes one marketed product, Arzerra, daratumumab in late stage clinical development, four antibodies in clinical development, and over 20 in-house and partnered pre-clinical programs. Co.'s Arzerra (ofatumumab) is a human monoclonal antibody which targets an epitope on the CD20 molecule. Co.'s proprietary technologies include the DuoBody technology, which creates antibodies that can target two molecules at once, and the HexaBody technology, which allows for the creation of more potent antibodies.

Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Dylan Van Haaften

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch